MDMA
Clearmind Medicine Raises $3.5 Million
Company plans to focus on alcohol use disorders.
The post Clearmind Medicine Raises $3.5 Million appeared first on Green Market Report.
Synthetic psychedelic medicine company Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) closed on a public offering on April 6 to raise $3.5 million.
Clearmind said it expects to use the net proceeds from the offering for general corporate purposes, which may include operating expenses, working capital, future acquisitions, research and development, including clinical and pre-clinical testing of its product candidates. The company also advised funds may be used for general capital expenditures.
According to the company’s prospectus, Clearmind plans to focus on psychedelic treatments for mental health disorders, including alcohol use disorders, binge drinking, and eating disorders. It’s specific focus at this time is on AUD.
The company also wrote in its offering prospectus, “We have completed a series of pre-clinical, investigational new drug, or IND, enabling studies in the United States and China that are required before we can study our compound for the first time in humans. These studies include pharmacokinetic and toxicological studies in rats and dogs in order to assess the safety profile of our compound and characterization of the drug metabolism.”
The company has conducted several metabolism studies on its 5-Methoxy-2-aminoindane, or MEAI, molecule to determine how it is digested in several species, as well as pre-clinical modeling to “characterize the effect of MEAI on alcohol consumption.”
What is MEAI?
MEAI is a synthetic molecule that has been studied and published in previous scientific papers. It belongs to the indane family of molecules which are closely related to MDMA.
The first appearance of MEAI was in a patent in 1998. It was seen as an alcohol replacement and used in a beverage called Pace. However, Health Canada deemed Pace an unauthorized and illegal product.
The scientist behind the Pace drink is Ezekiel Golan, and while the offering doesn’t mention him, the company website does post studies by Golan. Wikipedia states that Clearmind has wide intellectual property holdings to Golan’s patents.
The company also noted that it has submitted an IND request and intends to initiate the Phase I/IIa clinical study in the second quarter of 2023. The company also plans to submit applications to conduct the Phase I/IIa study in Europe and Israel.
The post Clearmind Medicine Raises $3.5 Million appeared first on Green Market Report.
mdma psychedelic cse nasdaq capital health canada research-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art